We expect the development efforts to intensify in the coming weeks and expect more companies entering the clinical trial Phase I, where the vaccine is tested in a small sample of healthy humans with moderate doses.
We also anticipate more companies advancing to Clinical Trial Phase II, where a larger sample of subjects of different age groups are tested for safety, efficiency, and determining the right dosing, and move to Clinical Phase III rapidly, where more complex and rigorous tests are performed on a much broader population.
MoneyShow Contributor
Our site uses cookies to personalize features and, via third-parties, to collect metrics on usage so that we can better tailor our site to the needs of our users. You can view our full cookie and privacy policies via the links below. To fully experience our site, please click Accept.